Johnson & Johnson (JNJ) Scheduled to Post Quarterly Earnings on Tuesday

Johnson & Johnson (NYSE:JNJ) is scheduled to announce its earnings results before the market opens on Tuesday, July 16th. Analysts expect the company to announce earnings of $2.42 per share for the quarter. Johnson & Johnson has set its FY 2019 guidance at $8.53-8.63 EPS and its FY19 guidance at $8.53-8.63 EPS.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, beating analysts’ consensus estimates of $2.03 by $0.07. The company had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The firm’s quarterly revenue was up .1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.06 EPS. On average, analysts expect Johnson & Johnson to post $9 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Shares of JNJ opened at $134.30 on Monday. The firm has a market cap of $356.57 billion, a P/E ratio of 16.42, a price-to-earnings-growth ratio of 2.32 and a beta of 0.70. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The company has a quick ratio of 1.13, a current ratio of 1.44 and a debt-to-equity ratio of 0.47. The firm has a 50-day simple moving average of $138.83.

In other news, Director Marillyn A. Hewson acquired 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The shares were purchased at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the acquisition, the director now owns 3,000 shares of the company’s stock, valued at approximately $419,040. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.23% of the company’s stock.

A number of equities analysts have recently weighed in on JNJ shares. Barclays upped their target price on from GBX 200 ($2.61) to GBX 210 ($2.74) and gave the company an “equal weight” rating in a report on Friday, June 21st. Credit Suisse Group set a $92.00 target price on Ashland Global and gave the company a “buy” rating in a report on Friday. Morgan Stanley set a $60.00 target price on Berry Global Group and gave the company a “hold” rating in a report on Wednesday, April 17th. Raymond James set a $8.00 target price on Superior Energy Services and gave the company a “buy” rating in a report on Wednesday, April 17th. Finally, Goldman Sachs Group set a $27.00 target price on Melco Resorts & Entertainment and gave the company a “buy” rating in a report on Tuesday, May 28th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Buy” and a consensus price target of $149.89.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: What does cost of debt say about a company’s financial health?

Earnings History for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.